{"id":11555,"date":"2024-06-21T09:37:00","date_gmt":"2024-06-21T09:37:00","guid":{"rendered":"https:\/\/www.healthnews.ie\/?p=11555"},"modified":"2024-07-05T09:06:01","modified_gmt":"2024-07-05T09:06:01","slug":"less-invasive-highly-sensitive-colorectal-cancer-diagnostic-techniques-under-review","status":"publish","type":"post","link":"https:\/\/www.healthnews.ie\/oncology\/less-invasive-highly-sensitive-colorectal-cancer-diagnostic-techniques-under-review\/","title":{"rendered":"Less invasive, highly sensitive: colorectal cancer diagnostic techniques under review"},"content":{"rendered":"\n<div style=\"background-color:#f2f2f2;color:#32373c\" class=\"wp-block-atomic-blocks-ab-profile-box round ab-has-avatar ab-font-size-14 ab-block-profile ab-profile-columns\"><div class=\"ab-profile-column ab-profile-avatar-wrap\"><div class=\"ab-profile-image-wrap\"><figure class=\"ab-profile-image-square\"><img loading=\"lazy\" decoding=\"async\" width=\"250\" height=\"250\" class=\"ab-profile-avatar wp-image-11560\" src=\"https:\/\/s3.eu-north-1.amazonaws.com\/cdn-site.mediaplanet.com\/app\/uploads\/sites\/94\/2024\/06\/07205739\/Bene-headshot_1024x1024.jpg\" alt=\"\" srcset=\"https:\/\/s3.eu-north-1.amazonaws.com\/cdn-site.mediaplanet.com\/app\/uploads\/sites\/94\/2024\/06\/07205739\/Bene-headshot_1024x1024.jpg 250w, https:\/\/s3.eu-north-1.amazonaws.com\/cdn-site.mediaplanet.com\/app\/uploads\/sites\/94\/2024\/06\/07205739\/Bene-headshot_1024x1024-125x125.jpg 125w\" sizes=\"auto, (max-width: 250px) 100vw, 250px\" \/><\/figure><\/div><\/div><div class=\"ab-profile-column ab-profile-content-wrap\"><h2 class=\"ab-profile-name\" style=\"color:#32373c\">Bene Ekine-Afolabi<\/h2><p class=\"ab-profile-title\" style=\"color:#32373c\">Founder and CEO, ZEAB Therapeutic Ltd.<\/p><div class=\"ab-profile-text\"><\/div><ul class=\"ab-social-links\"><\/ul><\/div><\/div>\n\n\n\n<p><em>A life sciences research company is driving innovation in colorectal cancer, highlighting the need for new applications of existing mutation profiling technologies.<\/em><\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<p>The worldwide burden of cancer affects upwards of <a href=\"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/full\/10.3322\/caac.21660\" target=\"_blank\" rel=\"noreferrer noopener\">244.6 million people<\/a>, making innovations in oncology diagnosis, treatment and management essential to improving patient outcomes, enhancing quality of life and reducing oncology mortality rates.&nbsp;With the global burden of cancer growing, research institutions are prioritising advanced diagnostics, effective treatments and comprehensive management strategies.<\/p>\n\n\n<div id=\"healt-1465970028\"><div class=\"healt-adlabel\">Advertisements<\/div><div id=\"healt-1652549500\" style=\"margin-top: 30px;margin-bottom: 30px;margin-left: auto;margin-right: auto;text-align: center;\"><a data-no-instant=\"1\" href=\"https:\/\/www.zeabtherapeutic.co.uk\/home\/\" rel=\"noopener\" class=\"a2t-link\" target=\"_blank\" aria-label=\"ZEAB 2\"><img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/s3.eu-north-1.amazonaws.com\/cdn-site.mediaplanet.com\/app\/uploads\/sites\/94\/2024\/06\/07205736\/ZEAB-2.jpg\" alt=\"\"  srcset=\"https:\/\/s3.eu-north-1.amazonaws.com\/cdn-site.mediaplanet.com\/app\/uploads\/sites\/94\/2024\/06\/07205736\/ZEAB-2.jpg 1563w, https:\/\/s3.eu-north-1.amazonaws.com\/cdn-site.mediaplanet.com\/app\/uploads\/sites\/94\/2024\/06\/07205736\/ZEAB-2-768x256.jpg 768w, https:\/\/s3.eu-north-1.amazonaws.com\/cdn-site.mediaplanet.com\/app\/uploads\/sites\/94\/2024\/06\/07205736\/ZEAB-2-1536x512.jpg 1536w\" sizes=\"auto, (max-width: 1563px) 100vw, 1563px\" width=\"750\" height=\"250\"  style=\"display: inline-block;\" \/><\/a><\/div><\/div>\n\n\n<h2 class=\"wp-block-heading\" id=\"h-innovative-colorectal-cancer-therapies\"><strong>Innovative colorectal cancer therapies<\/strong><\/h2>\n\n\n\n<p><a href=\"https:\/\/www.zeabtherapeutic.co.uk\/home\/\" target=\"_blank\" rel=\"noreferrer noopener\">ZEAB Therapeutic<\/a> is a life sciences research company focused on developing innovative cancer therapies, their main therapeutic focus being colorectal cancer.&nbsp;Bene Ekine-Afolabi, Founder and CEO of ZEAB Therapeutic, discusses the importance of early detection and treatment to improve patient outcomes.&nbsp;<\/p>\n\n\n\n<p>\u201cWe are a life science research company looking at drug development for colorectal cancer. Our mission is to undertake life science research for the development of cancer therapy,\u201d she says. \u201cWe are investigating new diagnostics and are continually advocating for less invasive, highly sensitive diagnostic techniques for a lesser cost.\u201d<\/p>\n\n\n\n<p>Working in collaboration with Cresset Discovery Services, UK and Human Metabolomics Technology, USA, the life sciences company is leveraging cutting-edge technologies to tackle colorectal cancer.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p>One of the biggest challenges with cancer today is the resistance to treatment and the recurrence.<\/p>\n<\/blockquote>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-technology-enhances-personalised-cancer-treatment\"><strong>Technology enhances personalised cancer treatment<\/strong><strong><\/strong><\/h2>\n\n\n\n<p>The integration of technologies like the MassARRAY system from <a href=\"https:\/\/www.agenabio.com\" target=\"_blank\" rel=\"noreferrer noopener\">AgenaBioscience<\/a>, in genetic analysis, offers precise mutation profiling, which can guide the development of much more personalised treatment plans, improving the success of many cancer therapies. A mass spectrometry-based system, the technology can test for a multitude of genetic markers and has become a powerful tool for genetic analysis and tumour mutation detection.<\/p>\n\n\n\n<p>\u201cWith the multiplex MassARRAY system, you can detect clinically relevant biomarkers in one to two days. It is a rapid, highly sensitive (allowing for detection of low mutation load approaching 1% VAF), and it is also economical in terms of both labour and costs involved,\u201d explains Ekine-Afolabi. \u201cIt has previously been used in the context of lung cancer research and diagnosis, and we are looking into how this technology can be applied to other oncology therapy areas.\u201d<\/p>\n\n\n<div id=\"healt-161864765\"><div class=\"healt-adlabel\">Advertisements<\/div><div id=\"healt-3400684908\" style=\"margin-top: 30px;margin-bottom: 30px;margin-left: auto;margin-right: auto;text-align: center;\"><a data-no-instant=\"1\" href=\"https:\/\/www.zeabtherapeutic.co.uk\/home\/\" rel=\"noopener\" class=\"a2t-link\" target=\"_blank\" aria-label=\"ZEAB 2\"><img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/s3.eu-north-1.amazonaws.com\/cdn-site.mediaplanet.com\/app\/uploads\/sites\/94\/2024\/06\/07205736\/ZEAB-2.jpg\" alt=\"\"  srcset=\"https:\/\/s3.eu-north-1.amazonaws.com\/cdn-site.mediaplanet.com\/app\/uploads\/sites\/94\/2024\/06\/07205736\/ZEAB-2.jpg 1563w, https:\/\/s3.eu-north-1.amazonaws.com\/cdn-site.mediaplanet.com\/app\/uploads\/sites\/94\/2024\/06\/07205736\/ZEAB-2-768x256.jpg 768w, https:\/\/s3.eu-north-1.amazonaws.com\/cdn-site.mediaplanet.com\/app\/uploads\/sites\/94\/2024\/06\/07205736\/ZEAB-2-1536x512.jpg 1536w\" sizes=\"auto, (max-width: 1563px) 100vw, 1563px\" width=\"750\" height=\"250\"  style=\"display: inline-block;\" \/><\/a><\/div><\/div>\n\n\n<h2 class=\"wp-block-heading\" id=\"h-promoting-early-cancer-detection\"><strong>Promoting early cancer detection<\/strong><strong><\/strong><\/h2>\n\n\n\n<p>Board committee member and occasional chair for the SEI Symposium for Cancer, Ekine-Afolabi is driving innovations in oncology diagnostics on a large scale.&nbsp;\u201cOne of the biggest challenges with cancer today is the resistance to treatment and the recurrence. The conference provides an opportunity to promote less invasive cancer therapy and diagnostic techniques, such as the MassARRAY System, advocating for early detection of cancer to mitigate its negative effects on patients,\u201d she concludes.<\/p>\n\n\n<!DOCTYPE html PUBLIC \"-\/\/W3C\/\/DTD HTML 4.0 Transitional\/\/EN\" \"http:\/\/www.w3.org\/TR\/REC-html40\/loose.dtd\">\n<html><body><div style=\"text-align:center\" class=\"wp-block-atomic-blocks-ab-button ab-block-button\"><a href=\"https:\/\/www.zeabtherapeutic.co.uk\/home\/\" target=\"_blank\" rel=\"noopener noreferrer\" class=\"ab-button ab-button-shape-rounded ab-button-size-medium fb-pixel\" style=\"color:#ffffff;background-color:#8e5398\">Click here to learn more<\/a><\/div>\n<\/body><\/html>\n","protected":false},"excerpt":{"rendered":"<p>A life sciences research company is driving innovation in colorectal cancer, highlighting the need for new applications of existing mutation profiling technologies. The worldwide burden of cancer affects upwards of 244.6 million people, making innovations in oncology diagnosis, treatment and management essential to improving patient outcomes, enhancing quality of life and reducing oncology mortality rates.&nbsp;With &hellip; <a href=\"https:\/\/www.healthnews.ie\/oncology\/less-invasive-highly-sensitive-colorectal-cancer-diagnostic-techniques-under-review\/\">Continued<\/a><\/p>\n","protected":false},"author":23,"featured_media":11568,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[2856],"tags":[5917],"class_list":["post-11555","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-oncology","tag-innovations-in-oncology-2024"],"acf":[],"featured_image_src":"https:\/\/s3.eu-north-1.amazonaws.com\/cdn-site.mediaplanet.com\/app\/uploads\/sites\/94\/2024\/06\/07205738\/GettyImages-1606882162-600x400.jpg","featured_image_src_square":"https:\/\/s3.eu-north-1.amazonaws.com\/cdn-site.mediaplanet.com\/app\/uploads\/sites\/94\/2024\/06\/07205738\/GettyImages-1606882162-600x600.jpg","author_info":{"display_name":"Your Future Career","author_link":"https:\/\/www.healthnews.ie\/author\/harveyodonnell\/"},"vicky_category_order":[{"category_id":2856,"order":"9"}],"vicky_index_order":"","_links":{"self":[{"href":"https:\/\/www.healthnews.ie\/wp-json\/wp\/v2\/posts\/11555","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.healthnews.ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.healthnews.ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.healthnews.ie\/wp-json\/wp\/v2\/users\/23"}],"replies":[{"embeddable":true,"href":"https:\/\/www.healthnews.ie\/wp-json\/wp\/v2\/comments?post=11555"}],"version-history":[{"count":4,"href":"https:\/\/www.healthnews.ie\/wp-json\/wp\/v2\/posts\/11555\/revisions"}],"predecessor-version":[{"id":11629,"href":"https:\/\/www.healthnews.ie\/wp-json\/wp\/v2\/posts\/11555\/revisions\/11629"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.healthnews.ie\/wp-json\/wp\/v2\/media\/11568"}],"wp:attachment":[{"href":"https:\/\/www.healthnews.ie\/wp-json\/wp\/v2\/media?parent=11555"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.healthnews.ie\/wp-json\/wp\/v2\/categories?post=11555"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.healthnews.ie\/wp-json\/wp\/v2\/tags?post=11555"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}